POSB63 Analysis of Cost per PASI75 and per Dlqi 0/1 Responder over 52 WEEKS in Patients with Moderate Plaque Psoriasis Initiated on Apremilast, Remaining on Apremilast or Switching to Biologics, and Patients Hypothetically Treated with Biol ...
Abstract
Authors
E Sotiriou V Chasapi E Gialeli J Katsantonis E Lazaridou N Rompoti O Neofotistou A Drosos KD Tomai E Rovithi C Kalinou E Papadavid P Aronis M Papageorgiou A Protopapa K Mavridou I Lefaki E Zafiriou K Krasagakis E Pokas A Kekki Z Anagnostopoulos N Antonakopoulos M Papakonstantis